Literature DB >> 9041173

The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.

D Rogaia1, F Grignani, R Carbone, D Riganelli, F LoCoco, T Nakamura, C M Croce, P P Di Fiore, P G Pelicci.   

Abstract

Translocations involving the HRX/ALL1 locus at chromosomal region 11q23 are among the most frequent cytogenetic abnormalities in acute leukemias. 11q23 translocations involve different chromosome partners and lead to the formation of HRX/ALL1 fusion proteins. The HRX/ALL1 protein is a putative transcription factor that has been implicated in developmental regulation in mammals. We report here the cellular localization of the HRX/ALL1 protein as well as that of the HRX/ALL1-eps15 fusion protein, the result of the t(1;11) (p32-q23) translocation of acute myeloid leukemias. The HRX/ALL1 protein was localized to both the cytoplasm and the nucleus. The nuclear pattern was characterized by diffuse staining, perinuclear accumulation, and localization within nuclear bodies of variable size, morphology, and number. The HRX/ALL1-eps15 localized exclusively to the nucleus within bodies that were smaller and more numerous than the HRX/ALL1 nuclear bodies. HRX/ALL1 fusion with an unknown partner in leukemia blasts with 11q23 abnormalities had similar morphological features. Thus, the fusion with eps15 alters the cellular compartmentalization of HRX/ALL1, providing a putative mechanism for activation of HRX/ALL1 by 11q23 abnormalities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041173

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization.

Authors:  James J-D Hsieh; Patricia Ernst; Hediye Erdjument-Bromage; Paul Tempst; Stanley J Korsmeyer
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

2.  The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.

Authors:  R T Luo; C Lavau; C Du; F Simone; P E Polak; S Kawamata; M J Thirman
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Novel sub-cellular localizations and intra-molecular interactions may define new functions of Mixed Lineage Leukemia protein.

Authors:  Amit Mahendra Karole; Swathi Chodisetty; Aamir Ali; Nidhi Kumari; Shweta Tyagi
Journal:  Cell Cycle       Date:  2018-12-10       Impact factor: 4.534

Review 4.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

5.  MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.

Authors:  Takayuki Tsujioka; Hideho Wada; Shunji Yamamori; Takemi Otsuki; Sinichiro Suemori; Toshinori Kondo; Hidekazu Nakanishi; Yoshimasa Suetsugu; Makoto Mikami; Takashi Sugihara
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

6.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Cynthia C Bartholomae; Marco Ranzani; Fabrizio Benedicenti; Lucia Sergi Sergi; Alessandro Ambrosi; Maurilio Ponzoni; Claudio Doglioni; Clelia Di Serio; Christof von Kalle; Luigi Naldini
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

7.  Rare Cytogenetic Anomalies in Two Pediatric Patients with Acute Leukemia

Authors:  Süreyya Bozkurt; Şule Ünal; Turan Bayhan; Fatma Gümrük; Mualla Çetin
Journal:  Turk J Haematol       Date:  2020-02-14       Impact factor: 1.831

8.  Eps15: a multifunctional adaptor protein regulating intracellular trafficking.

Authors:  Paul Mp van Bergen En Henegouwen
Journal:  Cell Commun Signal       Date:  2009-10-08       Impact factor: 5.712

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.